Dicerna Pharmaceuticals (DRNA) PT Raised to $42 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Price: $38.22 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
H.C. Wainwright analyst Ed Arce raised the price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $42.00 (from $40.00) while maintaining a Buy rating.
You May Also Be Interested In
- Zimmer Biomet (ZBH) PT Raised to $120 at Jefferies
- Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
- Bruker (BRKR) PT Raised to $70 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
